With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...
Within the mammoth defense bill, the Biosecure Act has the potential to raise new hurdles for certain life sciences companies ...
As Eli Lilly gears up to support its partnered athletes, Team USA and the Games themselves at the Milano Cortina 2026 Olympic ...
With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | On ...
The Swedish drugmaker has come up short in its effort to push imlifidase into treatment of the autoimmune condition ...
After a long run of regulatory stumbles and the recent wit | "Following the withdrawal of Ocaliva from the U.S. market, we ...
As it kicks off a pivotal phase 3 trial of its investigational treatment for Angelman syndrome (AS), Ionis Pharmaceuticals is ...
The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...
Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its bladder cancer med is still one to watch as it competes with heavy hitt | ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback